LT2976074T - Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomis - Google Patents
Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomisInfo
- Publication number
- LT2976074T LT2976074T LTEP13710850.2T LT13710850T LT2976074T LT 2976074 T LT2976074 T LT 2976074T LT 13710850 T LT13710850 T LT 13710850T LT 2976074 T LT2976074 T LT 2976074T
- Authority
- LT
- Lithuania
- Prior art keywords
- neuural
- dendritis
- cananbino
- anomalies
- antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/055728 WO2014146699A1 (en) | 2013-03-19 | 2013-03-19 | Antagonists of the cannabionoid receptor cb1 for use in the treatment of diseases associated with neuronal dendritic abnormalities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2976074T true LT2976074T (lt) | 2020-03-25 |
Family
ID=47901995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP13710850.2T LT2976074T (lt) | 2013-03-19 | 2013-03-19 | Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomis |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9662320B2 (lt) |
| EP (1) | EP2976074B1 (lt) |
| CY (1) | CY1122879T1 (lt) |
| DK (1) | DK2976074T3 (lt) |
| ES (1) | ES2781756T3 (lt) |
| HR (1) | HRP20200324T1 (lt) |
| HU (1) | HUE048755T2 (lt) |
| LT (1) | LT2976074T (lt) |
| PL (1) | PL2976074T3 (lt) |
| PT (1) | PT2976074T (lt) |
| RS (1) | RS60295B1 (lt) |
| SI (1) | SI2976074T1 (lt) |
| SM (1) | SMT202000164T1 (lt) |
| WO (1) | WO2014146699A1 (lt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| GB2549277B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder |
| GB2549278B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Use of cannabidivarin in the treatment of autism spectrum disorder |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| CN121221782A (zh) * | 2017-06-30 | 2025-12-30 | 傲拓神经科学公司 | 用于治疗抑郁的nk-1拮抗剂组合物和方法 |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| EP3669876A1 (en) * | 2018-12-18 | 2020-06-24 | Aelis Farma | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| EP4525836A4 (en) * | 2022-05-18 | 2026-02-25 | Hadasit Medical Res Services&Development Ltd | COMBINATION OF ENDOCANNABINOIDS AND MTOR INHIBITORS IN THE TREATMENT OF NEUROENDOCRINE NEOPLASMS |
| WO2024033521A1 (en) | 2022-08-12 | 2024-02-15 | GW Research Limited | Oral solid dosage forms comprising cannabinoids |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
| EP1606019A1 (en) | 2003-03-07 | 2005-12-21 | The University Court of The University of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
| JP2007529545A (ja) | 2004-03-19 | 2007-10-25 | アクソニクス，インコーポレイテッド | ダウン症候群の治療法 |
| WO2005120496A2 (en) | 2004-05-24 | 2005-12-22 | Regents Of The University Of California | TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE |
| WO2006012403A1 (en) * | 2004-07-20 | 2006-02-02 | Massachusetts Institute Of Technology | Methods of treatment: cell signaling and glutamate release |
| US20060276549A1 (en) * | 2005-05-13 | 2006-12-07 | Jacobson Peer B | Combination and use of drugs |
| LT1983984T (lt) | 2006-02-02 | 2018-06-11 | Novartis Ag | Tuberozinės sklerozės gydymas |
| US20080004313A1 (en) * | 2006-06-28 | 2008-01-03 | Mai De Ltd. | Preparation of crystalline polymorphs of rimonabant hydrochloride |
| US8003672B2 (en) * | 2008-04-21 | 2011-08-23 | Merck Sharp & Dohme Corp. | CB-1 receptor modulator formulations |
| WO2010020585A1 (en) * | 2008-08-18 | 2010-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Serotonin reuptake inhibitors for the treatment of rett syndrome |
| US20130058915A1 (en) | 2010-03-02 | 2013-03-07 | Children's Medica Center Corporation | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
-
2013
- 2013-03-19 HR HRP20200324TT patent/HRP20200324T1/hr unknown
- 2013-03-19 PT PT137108502T patent/PT2976074T/pt unknown
- 2013-03-19 PL PL13710850T patent/PL2976074T3/pl unknown
- 2013-03-19 HU HUE13710850A patent/HUE048755T2/hu unknown
- 2013-03-19 ES ES13710850T patent/ES2781756T3/es active Active
- 2013-03-19 WO PCT/EP2013/055728 patent/WO2014146699A1/en not_active Ceased
- 2013-03-19 SI SI201331699T patent/SI2976074T1/sl unknown
- 2013-03-19 US US14/778,266 patent/US9662320B2/en active Active
- 2013-03-19 EP EP13710850.2A patent/EP2976074B1/en active Active
- 2013-03-19 DK DK13710850.2T patent/DK2976074T3/da active
- 2013-03-19 LT LTEP13710850.2T patent/LT2976074T/lt unknown
- 2013-03-19 RS RS20200303A patent/RS60295B1/sr unknown
- 2013-03-19 SM SM20200164T patent/SMT202000164T1/it unknown
-
2020
- 2020-03-19 CY CY20201100258T patent/CY1122879T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2976074T3 (da) | 2020-03-30 |
| CY1122879T1 (el) | 2021-05-05 |
| EP2976074A1 (en) | 2016-01-27 |
| EP2976074B1 (en) | 2020-01-01 |
| US9662320B2 (en) | 2017-05-30 |
| WO2014146699A1 (en) | 2014-09-25 |
| US20160067235A1 (en) | 2016-03-10 |
| ES2781756T3 (es) | 2020-09-07 |
| PL2976074T3 (pl) | 2020-07-27 |
| HRP20200324T1 (hr) | 2020-06-12 |
| HUE048755T2 (hu) | 2020-08-28 |
| SMT202000164T1 (it) | 2020-05-08 |
| RS60295B1 (sr) | 2020-07-31 |
| SI2976074T1 (sl) | 2020-07-31 |
| PT2976074T (pt) | 2020-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT2976074T (lt) | Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomis | |
| SG11202012656WA (en) | Heterocyclic compounds useful in the treatment of disease | |
| DK3071593T3 (da) | Modificerede humane t-celle-receptorer med høj affinitet | |
| HUE059041T2 (hu) | Eljárás KIT-tel összefüggõ rendellenességek kezelésére alkalmas kompozíciók elõállítására | |
| LT2970456T (lt) | Būdai ir kompozicijos, skirti mrnr koduojamų antikūnų pristatymui | |
| LT2961410T (lt) | Pirazolopirimidino darinių naudojimas gydant su pi3k susijusius sutrikimus | |
| LT3363438T (lt) | Pakeistieji 2-azabiciklai ir jų panaudojimas kaip oreksino receptorių moduliatorių | |
| ME02917B (me) | Kombinacija dr5 agoniste i anti-pd--1 antagoniste i načini primjene | |
| LT2959005T (lt) | Medicininis naudojimas, susijęs su telomerų ilgėjimu | |
| HUE036750T2 (hu) | Alfa-v-béta-6 integrin antagonistákként alkalmazható naftiridin-származékok | |
| SI2968269T1 (sl) | Postopek priprave antagonistov beta 3 in vmesnih spojin | |
| HUE056006T2 (hu) | Kombináció Parkinson-kór kezelésére | |
| HUE053565T2 (hu) | Adagolási rendek Pompe betegség kezelésére | |
| EP3020707A4 (en) | P2X4 RECEPTOR ANTAGONIST | |
| LT3292875T (lt) | Kompozicijos ir būdai, skirti ligų gydymui | |
| IL242163B (en) | Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate | |
| LT3453723T (lt) | Antikūnai prieš asic1 ir jų panaudojimas | |
| DK2838539T3 (da) | Østrogenderivater til anvendelse i behandlingen af neurologiske forstyrrelser | |
| PL2768859T3 (pl) | Antagoniści IL17C do leczenia zaburzeń zapalnych | |
| SMT201500296B (it) | Antagonisti del recettore trpm8 | |
| LTPA2020511I1 (lt) | Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui | |
| HRP20181536T1 (hr) | Supstituirani piperidinil-tetrahidrokinolini i njihova uporaba kao antagonisti alfa-2c adrenoreceptora | |
| FR3004424B1 (fr) | Marchepied amovible d'aeronef, et aeronef | |
| LT3021873T (lt) | Kompozicija, skirta uždegiminių sąnarių ligų gydymui | |
| PL3954360T3 (pl) | Preparat farmaceutyczny węglowodanów do zastosowania terapeutycznego |